Issues to debate on the Women's Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma?

被引：30

作者：

Machens, K

Schmidt-Gollwitzer, K

机构：

[1] Schering AG, Res & Dev, D-13342 Berlin, Germany

[2] Humboldt Univ, Med Fachbereich, Berlin, Germany

来源：

HUMAN REPRODUCTION | 2003年 / 18卷 / 10期

关键词：

disease outcomes; epidemiology; HERS-HERS II; hormone replacement therapy; WHI; ESTROGEN/PROGESTIN REPLACEMENT; CARDIOVASCULAR-DISEASE; RISK; ESTROGEN; HEART; PROGESTIN; OUTCOMES;

D O I：

10.1093/humrep/deg406

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

In July 2002 the data of the prematurely stopped Estrogen plus Progestin study of the Women's Health Initiative (WHI) were presented in the Journal of the American Medical Association. The results of the Heart and Estrogen/Progestin Replacement Study (HERS/HERS II) were published in the same issue. The results of WHI for healthy postmenopausal women often are interpreted to be in analogy with the HERS/HERS II results for postmenopausal women with established coronary heart disease. As a result of HERS/HERS II and WHI, use of HRT in general became questionable. This is an unjustified judgement of HRT in general. This synoptic review and criticism of both studies will show the methodological weaknesses and their consequences and the reasons for limited generalizability of the study results from WHI and HERS/HERS II on normal HRT users.

引用

页码：1992 / 1999

页数：8

共 23 条

[1]

Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61

[2]

BOCK J, 1998, BESTIMMUNG STICHPROB, P96

[3] Comparison of tibolone and conjugated equine Estrogens effects on carotid arterv atherosclerosis of postmenopausal monkeys [J].

Clarkson, TB ;

Anthony, MS ;

Mikkola, TS ;

St Clair, RW .

STROKE, 2002, 33 (11) :2700-2703

[4]

Clarkson TB, 2002, INT J FERTIL WOMEN M, V47, P61

[5] THE RISK OF DETERMINING RISK WITH MULTIVARIABLE MODELS [J].

CONCATO, J ;

FEINSTEIN, AR ;

HOLFORD, TR .

ANNALS OF INTERNAL MEDICINE, 1993, 118 (03) :201-210

[6] Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women [J].

de Kleijn, MJJ ;

van der Schouw, YT ;

Verbeek, ALM ;

Peeters, PHM ;

Banga, JD ;

van der Graaf, Y .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (04) :339-345

[7] Clinical relevance of the HERS trial [J].

Gambacciani, M .

LANCET, 2002, 360 (9333) :641-641

[8]

Genazzani AR, 2002, CIRCULATION, V105, pE71, DOI 10.1161/01.CIR.0000012248.01291.CF

[9]

Genazzani AR, 2002, GYNECOL ENDOCRINOL, V16, P255

[10] Cardiovascular disease outcomes during 6.8 years of hormone therapy - Heart and Estrogen/progestin Replacement Study follow-up (HERS II) [J].

Grady, D ;

Herrington, D ;

Bittner, V ;

Blumenthal, R ;

Davidson, M ;

Hlatky, M ;

Hsia, J ;

Hulley, S ;

Herd, A ;

Khan, S ;

Newby, LK ;

Waters, D ;

Vittinghoff, E ;

Wenger, N .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (01) :49-57

← 1 2 3 →